Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 7 Endocrine 2 CNS 2 Tumor-Agnostic 1 Gynecologic 1 Breast 1

Conditions

Interventions

Gemcitabine 26 Paclitaxel 24 pembrolizumab 23 Carboplatin 22 Bevacizumab 18 Radiotherapy 16 Oxaliplatin 16 Erlotinib Hydrochloride 16 Nivolumab 15 Cisplatin 14 Capecitabine 14 Fluorouracil 13 Trastuzumab 12 Docetaxel 12 atezolizumab 11 Magnetic Resonance Spectroscopy 11 Leucovorin 11 Cyclophosphamide 11 Irinotecan 10 Ipilimumab 10 Vemurafenib 9 Everolimus 9 Cetuximab 9 cabozantinib 8 Radiosurgery 8 Afatinib 8 130-nm albumin-bound paclitaxel 8 trametinib 7 lenvatinib 7 durvalumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × belzutifan × Tumor-Agnostic × Clear all

NCT04976634 2025-04-06

MK-6482-016

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡